<?xml version="1.0" encoding="UTF-8"?>
<p>Current application: lopinavir (LPV) is an HIV-1 protease inhibitor administered in fixed-dose combination with ritonavir (LPV/r). Ritonavir is a potent cytochrome P450 3A4 (CYP3A4) inhibitor, which further potentiates the pharmacokinetic and pharmacodynamic properties of LPV [
 <xref rid="REF12" ref-type="bibr">12</xref>]. This combination has been found to effectively reduce viral load in HIV patients leading to an interest in its possible role in treating viruses with similar machinery [
 <xref rid="REF12" ref-type="bibr">12</xref>].
</p>
